Abstract 1494P
Background
Furoquitinib(F) is an orally highly selective tyrosine kinase inhibitor targeting VEGFR1,2,3. We previously reported some results of NCT04956146, which demonstrated that F plus PD-1 inhibitor sintilimab(S) and platinum-based chemotherapy(chemo) had encouraging efficacy and manageable toxicity as the first-line treatment for advanced naive EGFR- and ALK-negative nsq-NSCLC. Herein, we present updated results.
Methods
This single-arm, open-label, phase Ⅱ study consists of a safety lead-in phase (Part 1) and dose expansion phase (Part 2). In Part 1 the F taken orally at 5 mg (2 weeks on/ 1 weeks off, Q3W) plus S (200mg, iv, d1,Q3W) and chemo(Q3W). After 4∼6 cycles followed by maintenance therapy with F(RP2D) plus S and pemetrexed or not. DLT was observed for 1 cycle. The primary objective of Part 1 is to assess the safety and confirm the RP2D of F. The primary objective of Part 2 is to estimate the PFS and the secondary endpoints including ORR, DCR, OS, and safety.
Results
From February 2022 to May 2023, 26 pts were enrolled. The median age was 62 years, with males 92.3%, ECOG PS 0 73.1%, and the median sum of longest diameters (SLD) is 100.805mm. Pts with PD-L1 TPS ≥1%, <1%, and unknown were 14, 8, and 4 respectively. Of 20 evaluable pts, ORR and DCR were 80% and 100%. According to PD-L1 level, ORR was 91.7% and 57.1% for pts with PD-L1 TPS ≥1% and <1%. ORR was 60% for baseline SLD<median SLD and 100% for median SLD>median SLD. Median PFS was not reached yet. All pts experienced≥1 treatment-emergent adverse events (TEAEs). The most common Gr≥3 TEAEs (≥10% pts) were Neutrophil count decreased (42.3%), Anaemia(15.4%), Gamma-glutamyltransferase increased(11.5%) and hypertriglyceridaemia (11.5%).
Conclusions
This finding showed promising efficacy for fruquintinib combined with sintilimab and chemo in pts with advanced NSCLC as a first-line treatment with a manageable safety profile. This study might represent a potential treatment option for pts with unresectable or metastatic advanced naive EGFR- and ALK-negative nsq-NSCLC.
Clinical trial identification
NCT04956146; Release date: February 2, 2022.
Editorial acknowledgement
Legal entity responsible for the study
The First Affiliated Hospital with Nanjing Medical University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21